EGFR and non-small cell lung carcinoma: Our findings demonstrate that gender, age, smoking status, pathologic type of NSCLC, type of EGFR mutation, timing of targeted therapy, and brain metastasis do not affect the short-term efficacy of EGFR-TKIs in stage IV NSCLC patients, and oral administration of EGFR-TKIs results in clinical benefits for advanced NSCLC patients harboring EGFR mutations.